Annika Stange
Overview
Explore the profile of Annika Stange including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berger A, Lucke S, Abel U, Haag G, Grullich C, Stange A, et al.
Br J Cancer
. 2018 Jul;
119(2):170-175.
PMID: 29961759
Background: To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC). Methods: In this prospective...
2.
Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, et al.
Ann Surg Oncol
. 2015 May;
22 Suppl 3:S905-14.
PMID: 26001861
Background: Perioperative chemotherapy improves survival in patients with advanced esophagogastric cancer, but the optimal treatment regimen remains unclear. More intensive chemotherapy may improve outcome, but also increase toxicity and complications....
3.
Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, et al.
Gastric Cancer
. 2014 Apr;
18(2):314-25.
PMID: 24722800
Background: Neoadjuvant chemotherapy is an accepted standard of care for locally advanced esophagogastric cancer. As only a subgroup benefits, a response-based tailored treatment would be of interest. The aim of...
4.
Weber M, Bender K, von Gall C, Stange A, Grunberg K, Ott K, et al.
J Gastrointestin Liver Dis
. 2013 Mar;
22(1):45-52.
PMID: 23539390
Background & Aims: To prospectively assess whether changes in apparent diffusion coefficient (ADC) values or standardized uptake value (SUV) changes in 18F-fluorodeoxyglucose (FDG) PET correlate with treatment response under neoadjuvant...
5.
Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, et al.
Langenbecks Arch Surg
. 2012 Dec;
398(2):239-49.
PMID: 23269519
Purpose: Neoadjuvant treatment is an accepted standard approach for treating locally advanced esophago-gastric adenocarcinomas. Despite a response of the primary tumor, a significant percentage dies from tumor recurrence. The aim...
6.
Rahbari N, Lordick F, Fink C, Bork U, Stange A, Jager D, et al.
BMC Cancer
. 2012 Apr;
12:142.
PMID: 22480173
Background: Currently, it remains unclear, if patients with colon cancer and synchronous unresectable metastases who present without severe symptoms should undergo resection of the primary tumour prior to systemic chemotherapy....
7.
Berger A, von Gall C, Abel U, Delorme S, Kloor M, Ose J, et al.
BMC Cancer
. 2012 Mar;
12:108.
PMID: 22439666
Background: The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on...
8.
Lorenzen S, von Gall C, Stange A, Haag G, Weitz J, Haberkorn U, et al.
BMC Cancer
. 2011 Jun;
11:266.
PMID: 21702914
Background: 18-Fluorodeoxyglucose-PET (18F-FDG-PET) can be used for early response assessment in patients with locally advanced adenocarcinomas of the oesophagogastric junction (AEG) undergoing neoadjuvant chemotherapy. It has been recently shown in...